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Amyotrophic lateral sclerosis is a fatal neurodegenerative disease caused by the loss of
motoneurons. The precise molecular and cellular basis for neuronal death is not yet well
established, but the contemporary view is that it is a culmination of multiple aberrant biolog-
ical processes. Among the proposed mechanisms of motoneuron degeneration, alterations
in the homeostasis of RNA binding proteins (RBP) and the consequent changes in RNA
metabolism have received attention recently.The ribonuclease, angiogenin was one of the
first RBPs associated with familial and sporadic ALS. It is enriched in motoneurons under
physiological conditions, and is required for motoneuron survival under stress conditions.
Furthermore, delivery of angiogenin protects cultured motoneurons against stress-induced
injury, and significantly increases the survival of motoneurons in SODG93A mice. In this
overview on the role of angiogenin in RNA metabolism and in the control of motoneuron
survival, we discuss potential pathogenic mechanisms of angiogenin dysfunction relevant
to ALS and other neurodegenerative disorders. We also discuss recent evidence demon-
strating that angiogenin secreted from stressed motoneurons may alter RNA metabolism
in astrocytes.
Keywords: amyotrophic lateral sclerosis, RNA metabolism, angiogenin, RNA binding proteins, stress signals
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is fatal neurodegenerative dis-
ease with a late-onset, where motoneurons in the spinal cord and
brainstem die. After diagnosis, only about 25% of patients survive
beyond 5 years, with the majority suffering a fatal respiratory fail-
ure within 3–5 years. Most cases are believed to be sporadic, with
only about 10% of patients having a confirmed family history.
Several genetic alterations have been linked with ALS. Muta-
tions in the copper/zinc superoxide dismutase 1 (SOD1) gene,
responsible for circa 20% of the familial ALS forms and 1% of
“sporadic” cases, have been considered the major genetic cause of
ALS (Rosen et al., 1993). Recently, however, an expanded non-
coding GGGGCC repeat in C9ORF72 has been identified, which
seems to be responsible for about 24% of familial ALS (DeJesus-
Hernandez et al., 2011). In a Finnish cohort, the percentage of
linkage for this mutation was as high as 46% of ALS, putting this
as the most common genetic cause of ALS known to date (Renton
et al., 2011). Other important genes linked to ALS include two
RNA binding proteins, transactive response (TAR) DNA-binding
protein (TDP-43), and fused in sarcoma/translocated in liposar-
coma (FUS/TLS), which are associated with circa 4% of familial
ALS (reviewed by Lagier-Tourenne et al., 2010).
Still, the large majority of sporadic cases have no known
genetic component (reviewed by Valdmanis and Rouleau, 2008).
These observations have led to the hypothesis of ALS being an
oligogenic or polygenic disorder, a hypothesis that could also
explain the large number of familial ALS-associated gene muta-
tions that exhibit a relatively low penetrance (Valdmanis and
Rouleau, 2008).
ANGIOGENIN IN ALS
A clinical study initiated in Ireland has identified several mutations
in the angiogenin (ANG) gene in ALS patients of Irish and Scottish
background, both in familial and sporadic cases (Greenway et al.,
2006). Subsequent clinical studies confirmed the association of
these mutations with ALS, and identified new mutations in back-
grounds from Brazil, China, France, Germany, Italy, Netherlands,
Sweden, and USA (Table 1). Only one clinical study so far failed
to find a link between ANG gene mutations and ALS in an Italian
population (Corrado et al., 2007), but one can arguably reason
that such study was small (262 ALS patients) in comparison with
other reports (with an average of approximately 1,500 ALS patients
per study), and that some of the ANG mutations identified may
have a lower disease penetrance, similar to other ALS-associated
mutations (Valdmanis and Rouleau, 2008). More recently, a link
between angiogenin mutations and Parkinson’s disease has also
been demonstrated (Steidinger et al., 2011; van Es et al., 2011).
Angiogenin, firstly isolated from the conditioned medium of
colon carcinoma cells (Fett et al., 1985), is a member of the
pancreatic RNase A superfamily, recently renamed as vertebrate
secreted RNases (Li and Hu, 2012). This RNase is characterized
by an unusual low catalytic activity, but has a significant biolog-
ical ability to induce angiogenesis – hence its name (reviewed by
Tello-Montoliu et al., 2006; Table 2). Most of the ALS-linked ANG
mutations are predicted to affect the catalytic activity or cellular
localization of the enzyme (summarized in Table 1), suggesting
that the associated phenotype in ALS is mainly caused by loss of
activity. The mutants identified by Greenway and colleagues were
biochemically characterized (Crabtree et al., 2007), and all but the
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Table 1 | Angiogenin mutations associated with ALS.
Mutation Origin of
disease
Ethnicity Possible/known
effect on function
Oligogenic
model
Association with other
neurodegenerative conditions
M(−24)S (Wu et al., 2007; Gellera
et al., 2008)
Sporadic Europe
/America
Affect correct translation
M(−24)I (van Es et al., 2011) Sporadic Europe Affect correct translation Parkinson’s disease (van Es et al., 2011)
F(−13)L (Fernández-Santiago et al.,
2009; van Es et al., 2011)
Sporadic Europe Affect processing/traffic
F(−13)S (Gellera et al., 2008; van Es
et al., 2011)
Familial Europe Affect processing/traffic
G(−10)D (van Es et al., 2011) Sporadic Europe Affect protein function
P(−4)Q Sporadic Europe Affect processing/traffic
P(−4)S (Wu et al., 2007; van Es et al.,
2011)
Sporadic America Affect processing/traffic Parkinson’s disease (van Es et al., 2011)
Q12L (Greenway et al., 2006; van Es
et al., 2011)
Sporadic Europe Loss of activity
K17I (Greenway et al., 2006; Wu et al.,
2007; Millecamps et al., 2010; van Es
et al., 2011; van Blitterswijk et al., 2012)
Sporadic/
familial
Europe/
America
Loss of activity TDP-43
FUS/TLS
Frontotemporal dementia (van Es et al.,
2009)
K17E (Greenway et al., 2006; van Es
et al., 2009; van Es et al., 2011)
Sporadic Europe Loss of activity
S28N (Wu et al., 2007; van Es et al.,
2011)
Sporadic America Impaired nuclear
translocation/loss of
activity
R31K (Greenway et al., 2006; van Es
et al., 2011)
Sporadic Europe Impaired nuclear
translocation
C39W (Greenway et al., 2006; van Es
et al., 2011)
Familial Europe Loss of activity
K40I (Greenway et al., 2006; van Es
et al., 2011)
Sporadic Europe Loss of activity
I46V (Greenway et al., 2006; Gellera
et al., 2008; Conforti et al., 2008;
Paubel et al., 2008; Fernández-Santiago
et al., 2009; van Es et al., 2011)
Familial/
sporadic
Europe Loss of activity
K54E (Fernández-Santiago et al., 2009;
Millecamps et al., 2010; van Es et al.,
2011)
Sporadic/
familial
Europe Affect interaction with
nucleic acids/proteins
FUS/TLS
T80S (van Es et al., 2011) Sporadic Europe Tolerated/affect protein
function
F100I (van Es et al., 2011) Sporadic Europe Tolerate/benign
V103I (Zou et al., 2012) Sporadic Asia n.a.
P112L (Wu et al., 2007; van Es et al.,
2011)
Sporadic America Impaired nuclear
translocation/loss of
activity
V113I (Gellera et al., 2008; van Es et al.,
2011)
Sporadic/
familial
Europe Tolerated/affect protein
function
H114R (Gellera et al., 2008; van Es
et al., 2011)
Familial Europe Loss of activity
R121H (Paubel et al., 2008; Millecamps
et al., 2010; van Es et al., 2011)
Sporadic/
familial
Europe Loss of activity
R145C (van Es et al., 2011; Luigetti
et al., 2011)
Sporadic Europe n.a. SOD1
g.446C→T (Gellera et al., 2008; UTR
region)
Sporadic Europe Affect gene expression
n.a., not available/analyzed; Bold, These mutations have been biochemically characterized by Crabtree et al., 2007.
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Table 2 | Functions associated with angiogenin.
Function Mechanism RNAse activity-dependent Reference
Angiogenesis/wound
healing
Activation of PLC signal pathway Yes, depends on nuclear
translocation
Fett et al. (1985); Bicknell and Vallee (1988);
Moroianu and Riordan (1994); Liu et al.
(2001); Pan et al. (2012)
Activation of Erk1/2 signal pathway
rRNA synthesis
Neurite growth and
pathfinding
Unclear Yes – angiogenin inhibitor
blocks function
Subramanian and Feng (2007); Subramanian
et al. (2008)
Neuroprotection Activation of PI3K/Akt signal pathway Yes – loss of protection with
inactive ALS-associated
mutants
Kieran et al. (2008); Sebastia et al. (2009);
Steidinger et al. (2011); Skorupa et al. (2012)Engagement of HIF-1α
Paracrine signaling
Response to stress Inhibition of protein translation Yes – cleavage of rRNA Emara et al. (2010); Fu et al. (2009); Yamasaki
et al. (2009); Ivanov et al. (2011)Assembly of stress granules Yes – cleavage of tRNA
PLC, Phospholipase C; PI3K, Phosphatidylinositol 3-kinase.
ANGR31K mutant showed a marked reduction in catalytic activity
as predicted from structural studies.
Angiogenin has long been associated with different patho-
logical conditions, such as cancer and angiogenesis, neovascu-
larization associated with diabetic retinopathy and ischemia, as
well as rheumatoid arthritis (reviewed by Adams and Subra-
manian, 1999). Early studies with endothelial cells have identi-
fied angiogenin as a hypoxia-inducible, secreted protein which
acts as a potent inducer of rRNA transcription and neovascu-
larization (Moroianu and Riordan, 1994). The potential involve-
ment of angiogenin as a neuronal signaling molecule relevant
to ALS therefore came as a surprise. However a previous study
has associated another hypoxia-inducible, angiogenic, and neu-
rotrophic factor, VEGF, to play a role in ALS (Lambrechts et al.,
2003).
Angiogenin is expressed at high levels in the developing ner-
vous system both in the brain and spinal cord, predominantly in
neurons, and its activity has been shown to be necessary for neu-
rite extension/pathfinding in differentiated motoneuron-like cells
derived from pluripotent P19 carcinoma cells (Subramanian and
Feng, 2007; Figure 1A and Table 2). Interestingly, ALS-associated
angiogenin mutants failed to show the same activity (Subraman-
ian et al., 2008). Angiogenin is also expressed and enriched in
adult motoneurons (Greenway et al., 2006), and has been shown
to protect mature, cultured motoneurons against different ALS-
associated insults, such as excitotoxicity (Ca2+ mediated injury
resulting from glutamate receptor overactivation), hypoxia, and
endoplasmic reticulum stress. Angiogenin has been shown to pro-
mote and sustain cell survival signaling through AKT and ERK
kinase pathways (Kieran et al., 2008; Sebastia et al., 2009). In
addition, angiogenin delivery significantly increased the life-span
and improved motor function in SOD1G93A mice, an established
mouse model of ALS when delivered post-symptom onset (Kieran
et al., 2008).
PARACRINE ACTIVITY OF ANGIOGENIN
Recently our group has provided compelling evidence of a new
signaling pathway between motoneurons and astroglia mediated
by angiogenin (Skorupa et al., 2012). Our data indicate that angio-
genin is a neuronally produced protein which may constitutively
regulate RNA cleavage in motoneurons (Figure 1B). However
both transcription and secretion of angiogenin by motoneurons is
potently activated in response to stress, and motoneuron-derived,
secreted angiogenin is subsequently taken up nearly exclusively
by astroglia (Skorupa et al., 2012). This process involves synde-
cans as astrocyte receptors and clathrin-mediated endocytosis as
key uptake mechanism. Uptake of angiogenin into astrocytes sub-
sequently modifies the RNA profile of astroglia (Skorupa et al.,
2012). Furthermore, uptake of angiogenin into astrocyte was
shown to be required for the protection of angiogenin from stress-
induced motoneuron injury (Skorupa et al., 2012). An attractive
hypothesis derived from these studies is that angiogenin may rep-
resent a “help me” signal secreted from stressed motoneurons that
stimulates defense mechanisms in astrocytes (Figure 1B). Like-
wise, it is possible that secreted angiogenin may act on endothelial
cells to promote angiogenesis, thereby increasing blood supply to
“stressed” motoneurons (Figure 1B).
RNA METABOLISM IN ALS AND OTHER
NEURODEGENERATIVE DISEASES
RNA cleavage in motoneurons, astrocytes, or other target cells
by angiogenin may significantly alter their RNA metabolism. The
current knowledge about RNA metabolism in neurons has been
comprehensively reviewed by Strong (2010). Neurons present
asymmetrical protein translation, i.e., neurons are able to direct
a site-specific protein translation by “packaging” and transport-
ing quiescent mRNA through the cell within ribonucleoprotein
(RNP) complexes, also known as RNA granules. There are three
main types of RNA granules in a mature neuron: (a) transport
granules, which contain translationally silent RNA; (b) P-bodies
or degradative granules, responsible of mRNA decay; and (c) stress
granules (SG), which sequester mRNA in a translationally silent
state at times of neuronal injury.
Stress granules assemble transiently under stressful conditions
such as hypoxia, starvation, or exposure to radiation and are able
to reprogram RNA translation. Interestingly, angiogenin has also
been linked to SG assembly (Emara et al., 2010). Moreover, both
TDP-43 and FUS are known to associate with SG (Colombrita
et al., 2009; Bosco et al., 2010; Liu-Yesucevitz et al., 2010; reviewed
in Dewey et al., 2012). TDP-43 and FUS seem to be implicated in
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FIGURE 1 | Schematic representation of the main known functions
of angiogenin. (A) Neurite growth and pathfinding. Angiogenin is
found in high levels during embryogenesis, both on the brain and spinal
cord; (B) Neuroprotection in ALS models. In situations of stress, such
as starvation and hypoxia, angiogenin expression is up-regulated in
motoneurons. Angiogenin is secreted and endocytosed by surrounding
astroglia and close endothelial cells. In astroglia, angiogenin processes
RNA, possibly altering the protein translation profile. A similar
phenomenon is proposed to happen in endothelial cells, culminating in
the production of survival signals (astroglia) and angiogenesis
(endothelial cells), possibly resulting in increase of blood flow in
affected areas.
transcription regulation, splicing regulation, miRNA processing,
mRNA transport, translation, and decay (reviewed by Lagier-
Tourenne et al., 2010; Figure 2). The detailed role of angiogenin
in the regulation of these processes therefore warrants further
investigations.
Angiogenin is known to stimulate the transcription of rRNA
(Li and Hu, 2010) and represents the ribonuclease responsible for
the generation of tRNA-derived, stress-induced small RNAs, also
known as tiRNAs (Fu et al., 2009; Yamasaki et al., 2009; Ivanov
et al., 2011). These tiRNAs are capable of inhibiting protein trans-
lation when cells are submitted to stress conditions, such as heat
shock, hypothermia, hypoxia, starvation, and radiation. Further-
more, in an elegant study, Emara et al. (2010) demonstrated that
angiogenin-generated tiRNAs are able to stimulate the formation
of SG. This observation potentially puts angiogenin in interaction
with other SG-related proteins, such as TDP-43 and FUS/TLS in
the context of ALS.
In our model of angiogenin-mediated neuroprotection, we
observed the intraneuronal generation of RNA fragments of con-
sistent size to tiRNAs, however angiogenin internalized by astro-
cytes generates RNA fragments of different sizes, suggesting that
it processes different substrates (Skorupa et al., 2012). RNA pro-
cessing in astroglia may therefore specifically alter the transla-
tional output of astroglia. Two possible mechanisms of action
emerge from these observations: (1) angiogenin could inhibit
the astrocytic production of toxic molecules, or (2) angiogenin
would induce the astrocytic production of protective molecules.
In both hypotheses, angiogenin actions could be mediated by
the reprogramming of the protein profile of astrocytes. A third
possibility, where angiogenin would be both down-regulating
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FIGURE 2 | Schematic representation of RNA metabolism in mammalian cells. Marked in red are the processes where angiogenin has been shown to be
involved.
death signals and up-regulating survival signals cannot be ruled
out (Figure 1).
Supporting the first scenario, evidence for a pathological
role of glia on motoneurons death in ALS has been clearly
established, and activated microglia, astrogliosis, and infiltrat-
ing lymphocytes coincide with motoneuron injury in ALS
spinal cord (Appel et al., 2011). In addition, the toxic effect
of astrocytes derived from ALS patients or mouse models on
motoneurons has been recently reported (Diaz-Amarilla et al.,
2011; Haidet-Phillips et al., 2011). Further studies are therefore
required to explore whether angiogenin alters the secretome of
astroglia.
CONCLUSION
It is not yet clear whether the pathological role of astrocyte
and/or other glial cells on ALS disease progression is sim-
ply that of increased toxicity, or instead of failure to pro-
vide adequate protection against stress signals – internal and/or
external. One appealing possibility is a model where an ini-
tial stress signal (“hit”) would trigger neurotoxicity. In this
scenario, angiogenin (or other ALS-associated proteins) could
function as a “rescue message” to astrocytes. Loss-of-function
mutations in the ANG gene could dramatically increase the
susceptibility of motoneurons to stress-induced injury. From
a therapeutic perspective, angiogenin delivery may be a viable
approach for the treatment of ALS or other neurodegenerative
disorders.
Of note, a first “hit” could also be the presence of another
ALS-related mutation, such as TDP-43, FUS, or SOD1 mutant pro-
teins (the latter known to exercise its pathological effect through a
toxic gain-of-function profile). Cases of ALS patients with muta-
tions in more than one gene have been observed (see Table 1 for
reference), as well as the observation of angiogenin mutations, pre-
viously linked to ALS, in healthy control subjects (Corrado et al.,
2007). This so-called“double hit”hypothesis could be one possible
explanation for an ALS scenario where many minor insults or indi-
vidually harmless genetic polymorphisms put together or acting
synergistically, could cause the disease phenotype. Corroborating
this hypothesis, a recent study has demonstrated that the frequency
of families with multiple mutations is higher than one might
expect on the basis of chance (P= 1.57× 10−7; van Blitterswijk
et al., 2012).
Notwithstanding the cumulative evidence gathered thus far,
the role of angiogenin in the physiology and pathophysiology
www.frontiersin.org November 2012 | Volume 6 | Article 167 | 5
Aparicio-Erriu and Prehn Angiogenin and RNA metabolism in ALS
of the nervous system, in particular ALS and Parkinson’s dis-
ease, requires further investigation. It is tempting to speculate
that the neuroprotective role of angiogenin occurs via a dou-
ble action both on motoneurons and astrocytes through the
reprogramming of protein synthesis. Therefore, the identifica-
tion of angiogenin substrates and products, together with the
understanding of their physiological roles during the context of
neurodegeneration may pave the way to new exciting therapeutic
possibilities.
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